September 2025 P&T formulary decisions (partial) — Pharmacy & Specialty Drugs coverage criteria
Customize your policy alerts
Sign up for all Aspirus Arise policy alerts
Know when Aspirus Arise releases new policies or updates existing guidance.
Monitor payer policy activity
Summarizes Pharmacy & Therapeutics Committee decisions on formulary status, new indications, generics, and dosage-form launches for multiple drugs that affect Aspirus Medicare formulary placement and prior authorization/step therapy rules.
New strengths and formulations for Zoryve (roflumilast) were released to support pediatric use and new indications, and were assigned formulary statuses.
New 5 mg and 7.5 mg selumetinib (Koselugo) sprinkle capsules were launched to support pediatric patients ≥1 year; Koselugo listed as Formulary.
New vial size for Krystexxa (pegloticase) — 8 mg/50 mL IV vial — was launched and listed as Non-Formulary.
New Evexithroid (thyroid) tablet strengths (45 mg and 75 mg) were launched and listed as Non-Formulary.
Vyscoxa (celecoxib) 10 mg/mL oral suspension launched and listed as Non-Formulary.
Tonmya (cyclobenzaprine) 2.8 mg sublingual tablet for fibromyalgia launched and listed as Non-Formulary.
Beizray (docetaxel-albumin) 80 mg/4 mL IV vials approved via 505(b)(2) pathway and listed as Non-Formulary.
Keytruda Qlex (pembrolizumab-berahyaluronidase alfa) subcutaneous formulation launched and listed as Non-Formulary.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.